<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946166</url>
  </required_header>
  <id_info>
    <org_study_id>HSC2009-183H</org_study_id>
    <nct_id>NCT00946166</nct_id>
  </id_info>
  <brief_title>Impact of Statins on Cytokine Expression in Pneumonia</brief_title>
  <official_title>Impact of Statins on Cytokine Expression in Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are conducting a study to determine the effects of a cholesterol-lowering&#xD;
      medication, called simvastatin on pneumonia. People in the study will be in the hospital&#xD;
      because they have pneumonia. The people will also have a medical condition like heart&#xD;
      disease, diabetes, stroke or high cholesterol for which cholesterol-lowering medication has&#xD;
      been shown to prevent future disease and/or death but are not taking a cholesterol-lowering&#xD;
      medication when they go to the hospital. Some people will get treated with antibiotics only&#xD;
      and other people will get antibiotics and simvastatin while they are in the hospital. The&#xD;
      study will compare the effects the combination of simvastatin and antibiotics has on people&#xD;
      with pneumonia to treatment with antibiotics alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left institution.&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine (TNF alpha, IL-1beta, IL-6, IL-8, IL-10) levels</measure>
    <time_frame>enrollment, 24h, 48h, 72h, hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30-days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <condition>Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive standard treatment for pneumonia and a simvastatin-like placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive simvastatin in addition to standard pneumonia treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>40 mg daily in the evening for a maximum of 14 days</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Simvastatin-like placebo administered daily in the evening for a maximum of 14 days</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age,&#xD;
&#xD;
          -  Chart documentation by a clinician of an initial working diagnosis of pneumonia within&#xD;
             24 hours of admission,&#xD;
&#xD;
          -  Chest x-ray or other imaging evidence consistent with pneumonia within 48 hours of&#xD;
             hospitalization, and&#xD;
&#xD;
          -  One of the following severity criteria: pneumonia severity index class III or higher,&#xD;
             at least 2/5 components of the CURB-65, or ICU level care within 24 hours of&#xD;
             admission.&#xD;
&#xD;
          -  Having one Food and Drug Agency approved indication for statin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Treatment with one or more doses of a statin within 30-days prior to admission&#xD;
             or during the current hospitalization.&#xD;
&#xD;
          -  Hospitalization &gt; 24 hours at time of the diagnosis of pneumonia.&#xD;
&#xD;
          -  Hospitalization &gt; 48 hours at time of study enrollment.&#xD;
&#xD;
          -  Residence in a skilled nursing facility.&#xD;
&#xD;
          -  Previously diagnosed human immunodeficiency virus infection with a current CD4 count &lt;&#xD;
             200 cells/mm.&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Patient or family decision to limit medical care (&quot;comfort measures only&quot;).&#xD;
&#xD;
          -  Known allergy to statin therapy.&#xD;
&#xD;
          -  Active or planned pregnancy or breastfeeding.&#xD;
&#xD;
          -  Inability to take oral medications at the time of study enrollment.&#xD;
&#xD;
          -  Pre-existing liver disease or AST/ALT &gt; 10% the upper limit of normal.&#xD;
&#xD;
          -  Creatinine phosphokinase (CPK or CK) &gt; 50% above the upper limit of normal.&#xD;
&#xD;
          -  Partial ileal bypass.&#xD;
&#xD;
          -  Concurrent treatment with potential interacting drugs: ketoconazole, itraconazole,&#xD;
             amiodarone, clarithromycin, erythromycin, cyclosporine, danazol, niacin, protease&#xD;
             inhibitors, telithromycin, verapamil, gemfiborzil, ezetimibe (Zetia), nefazodone.&#xD;
&#xD;
          -  Transfer from an outside hospital.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric M Mortensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center/ South Texas Veterans Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L Murphy Memorial Veterans Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>statins</keyword>
  <keyword>cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

